CytRx NantCell Agreement Brings Cash and Experience

Company Overview

CytRx Corporation (NASDAQ: CYTR) is a clinical-stage pharmaceutical company specializing in oncology. In particular, the company is focused on anti-cancer drugs that employ linker technologies to enhance the accumulation and release of drugs at the tumor site. CytRx’s lead product candidate is aldoxorubicin, an alternative to widely-used chemotherapy agent doxorubicin.

Aldoxorubicin is currently in late-stage development for the treatment of relapsed soft tissue sarcoma (STS), and is also being evaluated for several other cancer indications including small-cell lung cancer. The company is also engaged in the development of a new class of oncology candidates utilizing their proprietary LADR technology.

CytRx was originally incorporated in 1985, and is headquartered in Los Angeles, California.


Pipeline and Products

The company’s primary product candidate is designed to improve on doxorubicin, a widely-used chemotherapy agent. Aldoxorubicin binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of the tumor. This mechanism is outlined below:

Source: Company Presentation

Other potential advantages of aldoxorubicin include the potential to increase the total doxorubicin dose, a reduction in certain adverse events associated with doxorubicin, and improved efficacy.

The potential applications of aldoxorubicin are summarized in the CytRx’s pipeline:

Source: Company Presentation


The company released updated Phase III data in November 2016. Aldoxorubicin demonstrated a significant improvement in progression-free survival over the investigator’s choice therapy in 246 patients with either leiomyosarcoma or liposarcoma. It also achieved a statistically significant improvement in the disease control rate.

CytRx met with the FDA in March 2017 to discuss a regulatory approval pathway. Aldoxorubicin was subsequently granted orphan drug designation and no further clinical trials were requested. At this time, the company expects to initiate a rolling new drug application for aldoxorubicin as a treatment for STS in the fourth quarter of 2017, with commercialization projected for 2018.

The company is also in the early stages of development of a compound known as DK049. This drug is a derivative of the chemotherapeutic agent gemcitabine combined with a dual releasing linker. CytRx released its initial findings at the 2016 annual meeting of the American Association of Cancer Research. Preclinical data in animal models of pancreatic, ovarian, and non-small cell lung cancers show superior anti-tumor effects compared to gemcitabine while using approximately one-sixth of the dose.


Recent Developments

  • On July 28, 2017, CytRX announced that it has entered a strategic license agreement with NantCell, Inc., for the exclusive rights to develop and commercialize aldoxorubicin for all indications. NantCell is a private subsidiary of NantWorks, LLC, is a clinical stage immuno-oncology company focused on developing novel molecularly targeted therapeutics including antibody, T-cell and NK cell based treatments for patients with cancer.  Under the terms of the agreement, NantCell purchased $13 million of CytRx’s common stock at a price of $1.10 (a 92 percent premium to the prevailing market price), and will make up to $343 million in payments tied to regulatory approvals and commercial milestones. CytRx will also receive double-digit royalties for sales of aldoxorubicin related to STS, and mid to high single digit royalties for all other indications. NantCell will be responsible for all future development, manufacturing, and commercialization expenses. CytRx also issued NantCell a warrant to purchase 3 million shares of common stock at a price of $1.10 within the next 18 months. We also note that CytRx made a $5 million payment on its long-term loan facility in conjunction with the transaction.


  • In May 2017, the company sold approximately 30 million shares at a purchase price of $0.50. Net proceeds from the transaction were approximately $13.9 million.



Second Quarter Earnings Review

In the quarter ended June 30, 2017, the company did not record any revenue as compared to $100,000 in the second quarter of 2016. Other than licensing agreements (such as that described above), the company does not yet generate revenues from the sale of products.

Research and development expenses fell more than 50 percent year-over-year to $6.2 million.  General and administrative expenses also fell nearly 50 percent to $3.1 million. Accordingly, the company’s net loss decreased from $18.3 million ($0.27 per share) in the second quarter of 2016 to $14.4 million ($0.10 per share) in the most recent quarter.

At June 30, 2017, CytRx listed cash and equivalents of $55.0 million and debt equal to $15.8 million, yielding a net cash position of $39.2 million. Stockholders’ equity totaled $19.2 million. As discussed above, subsequent to June 30, 2017, the company received a $13 million investment from NantCell and reduced debt by $5 million.


 Stock Influences

  • Regulatory approval for aldoxorubicin for the treatment of STS;
  • Clinical trial data regarding additional applications of aldoxorubicin; and
  • Progress related to the development of DK049.

Risk Factors

  • Although aldoxorubicin is currently projected to reach commercialization in 2018, it could face material delays;
  • If aldoxorubicin is materially delayed, the company could be forced to seek additional financing and possibly lead to the dilution of existing shareholders;
  • Doxorubicin is a widely used anti-cancer drug and new versions (i.e. potential competitors) are continually being developed; and
  • The company may not be able to develop any other product candidates using its proprietary technology.


Stock Performance


As of August 8, 2017, shares of CytRx closed at $0.64, yielding a market capitalization of approximately $100 million. The stock hit a 12-month high of $1.00 immediately after the agreement with NantCell was announced, but has traded between $0.60 and $0.70 since second quarter earnings were released. As shown above, the stock has experienced multiple enthusiastic spikes only to retreat shortly thereafter. Still, shares are up 70 percent year-to-date.




Aldoxorubicin offers several potential improvements to existing chemotherapy. Furthermore, the agreement with NantCell ensures that CytRx has an experienced partner to develop and commercialize aldoxorubicin for all indications. The agreement also provides the company with an immediate infusion of cash. It is also noteworthy that NantCell will be responsible for all future development, manufacturing, and commercialization expenses


However, while the company has discussed a regulatory pathway with the FDA, it must ensure that aldoxorubicin receives approval before it begins to generate recurring revenues. CytRx’s cash reserves seem to be sufficient for now, but it is uncertain how long the approval process will take.



Limited Time Offer VIP Mobile Alerts

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Traders” to the phone number “25827” from your cell phone***






Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Ivan Neilson, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ about forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve several risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.